Evidence map›Paper›PMID 37252012›Full record

ArticlePathogens & immunity2023

A Community-Driven Framework to Prioritize the Use of Donated Human Biological Materials in the Context of HIV Cure-Related Research at the End of Life.

Karine Dubé, Thomas J Villa, Jeff Taylor, Andy Kaytes, David J Moore, Susan J Little, Antoine Chaillon, Davey M Smith, Sara Gianella

Open access · diamondAbstract read
In one paragraph

Article in Pathogens & immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Karine DubéDivision of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA.
Thomas J VillaHIV Obstruction by Programmed Epigenetics Delaney Collaboratory Community Team, San Francisco, CA.
Jeff TaylorReversing Immune Dysfunction Delaney Collaboratory for HIV Cure Research Community Advisory Board, La Jolla, CA.
Andy KaytesReversing Immune Dysfunction Delaney Collaboratory for HIV Cure Research Community Advisory Board, La Jolla, CA.
David J MooreDepartment of Psychiatry, School of Medicine, University of California San Diego, San Diego, CA.
Susan J LittleDivision of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA.
Antoine ChaillonDivision of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA.
Davey M SmithDivision of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA.
Sara GianellaDivision of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego, La Jolla, CA.
University of California, San Diego · USUniversity of California System · USAdvisory Board Company (United States) · USDesert AIDS Project · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
HOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI Lishomwa C Ndhlovu, Melanie Maria Ott · 2021 to 2026
$32.2M
Project-004P01AI169609 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 2022 to 2026
$10.6M
Training Program for Scientists Conducting Research to Reduce HIV Health DisparitR25MH067127 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily A Arnold, Torsten Brian Neilands · 2003 to 2026
$5.4M
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P01 AI169609NIAID NIH HHS UM1 AI164559NIMH NIH HHS R25 MH067127
6 · The paper itself

Abstract

Initiated in 2017 after extensive community engagement, the Last Gift program enrolls altruistic volunteers willing to donate their cells and tissues at the end of life to allow studies on HIV reservoir dynamics across anatomical sites. As the Last Gift team received tissue requests outside the scope of HIV cure research, we noticed the absence of guiding frameworks to help prioritize the use of altruistically donated human biological materials. In this commentary, we present a proposed framework for prioritizing the use of donated human biological materials within and outside the end-of-life (EOL) HIV cure research context, using the Last Gift study as an example. First, we discuss regulatory and policy considerations, and highlight key ethical values to guide prioritization decisions. Second, we present our prioritization framework and share some of our experiences prioritizing requests for donated human biological materials within and outside EOL HIV cure research.

Indexed as

donationsEnd of lifeethicsHIV cure researchhuman biological materialsimmunitypathogenstissuesvirology

Identifiers

PMID37252012
PMCPMC10225111
OpenAlexW4378220131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.